Allogeneic hematopoietic stem cell transplantation is curative in myelofibrosis, and current
prognostic scoring systems aim to select patients for transplantation. Here, we aimed to …

Mutational profiling has demonstrated utility in predicting the likelihood of disease
progression in patients with myelofibrosis (MF). However, there is limited data regarding the …

Although allogeneic hematopoietic cell transplantation (allo-HCT) is the only curative
treatment for myelofibrosis (MF), data are limited on how molecular markers predict …

Purpose To develop a prognostic system for transplantation-age patients with primary
myelofibrosis (PMF) that integrates clinical, cytogenetic, and mutation data. Patients and …

Hematopoietic cell transplantation (HCT) provides potentially curative treatment for patients
with myelofibrosis (MF). HCT outcomes are associated with the Dynamic International …

International collaborations over the years have produced a series of prognostic models for
primary myelofibrosis (PMF), including the recently unveiled mutation-enhanced …

New options for medical therapy and risk scoring systems containing molecular data are
leading to increased complexity in the management of patients with myelofibrosis. To inform …

Molecular genetics may influence outcome for patients with myelofibrosis. To determine the
impact of molecular genetics on outcome after allogeneic stem cell transplantation, we …

Abstract Studies by the International Working Group showed that the prognosis of
myelofibrosis patients is predicted by the Dynamic International Prognostic Scoring System …

To define a prognostic model for predicting outcome of reduced‐intensity allogeneic stem
cell transplantation (RIC‐ASCT) for myelofibrosis we evaluated 150 homogenously treated …